Evolving role of uPA/uPAR system in human cancers

Cancer Treatment Reviews

Volumn 34, Issue 2, 2008, Pages 122-136

  Dass, Kathleen ^a   Ahmad, Aamir ^a   Azmi, Asfar S ^a   Sarkar, Sarah H ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer biomarkers; Extracellular matrix degradation; Invasion; Metastasis; PAI 1; uPA; uPAR

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE; TUMOR MARKER; UROKINASE; UROKINASE RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; BASEMENT MEMBRANE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RESEARCH; CARCINOGENICITY; CELL INVASION; CHONDROSARCOMA; COLORECTAL CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; INTERNALIZATION; KIDNEY CANCER; LEUKEMIA; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; METASTASIS; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHEOCHROMOCYTOMA; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; STOMACH CANCER; THYROID CANCER; UTERINE CERVIX CANCER; VON HIPPEL LINDAU DISEASE;

HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN INACTIVATORS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 40649121508     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.10.005     Document Type: Review

References (88)

1. National Cancer Institute. Cancer statistics 2007. www.cancer.gov.
2. Stillfried G.E., Saunders D.N., and Ranson M. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res 9 1 (2007) R14
3. Fisher J.L., Mackie P.S., Howard M.L., Zhou H., and Choong P.F. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 7 6 (2001) 1654-1660
4. Swiercz R., Wolfe J.D., Zaher A., and Jankun J. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 4 4 (1998) 869-877
5. Wang Y., Dang J., Johnson L.K., Selhamer J.J., and Doe W.F. Structure of the human urokinase receptor gene and its similarity to CD59 and the Ly-6 family. Eur J Biochem 227 1-2 (1995) 116-122
6. Farias-Eisner R., Vician L., Silver A., Reddy S., Rabbani S.A., and Herschman H.R. The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation. J Neurosci 20 1 (2000) 230-239
7. Llinas P., Le Du M.H., Gardsvoll H., Dano K., Ploug M., Gilquin B., et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 24 9 (2005) 1655-1663
8. Huai Q., Mazar A.P., Kuo A., Parry G.C., Shaw D.E., Callahan J., et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 311 5761 (2006) 656-659
9. Carmeliet P., Moons L., Dewerchin M., Rosenberg S., Herbert J.M., Lupu F., et al. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 140 1 (1998) 233-245
10. Koopman J.L., Slomp J., de Bart A.C., Quax P.H., and Verheijen J.H. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor. J Biol Chem 273 50 (1998) 33267-33272
11. Kobayashi H., Fujishiro S., and Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54 24 (1994) 6539-6548
12. Zhou H.M., Bolon I., Nichols A., Wohlwend A., and Vassalli J.D. Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res 61 3 (2001) 970-976
13. Herz J., Clouthier D.E., and Hammer R.E. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 71 3 (1992) 411-421
14. Binder B.R., Mihaly J., and Prager G.W. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 97 3 (2007) 336-342
15. Nykjaer A., Conese M., Christensen E.I., Olson D., Cremona O., Gliemann J., et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 16 10 (1997) 2610-2620
16. Nykjaer A., Christensen E.I., Vorum H., Hager H., Petersen C.M., Roigaard H., et al. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol 141 3 (1998) 815-828
17. Roca C., Primo L., Valdembri D., Cividalli A., Declerck P., Carmeliet P., et al. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res 63 7 (2003) 1500-1507
18. Soff G.A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96 6 (1995) 2593-2600
19. Bajou K., Maillard C., Jost M., Lijnen R.H., Gils A., Declerck P., et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23 41 (2004) 6986-6990
20. Leik C.E., Su E.J., Nambi P., Crandall D.L., and Lawrence D.A. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 4 12 (2006) 2710-2715
21. Leissner P., Verjat T., Bachelot T., Paye M., Krause A., Puisieux A., et al. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 6 (2006) 216
22. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4 8 (1998) 923-928
23. Gutierrez L.S., Schulman A., Brito-Robinson T., Noria F., Ploplis V.A., and Castellino F.J. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60 20 (2000) 5839-5847
24. McMahon G.A., Petitclerc E., Stefansson S., Smith E., Wong M.K., Westrick R.J., et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276 36 (2001) 33964-33968
25. Stefansson S., McMahon G.A., Petitclerc E., and Lawrence D.A. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 9 19 (2003) 1545-1564
26. Devy L., Blacher S., Grignet-Debrus C., Bajou K., Masson V., Gerard R.D., et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16 2 (2002) 147-154
27. Li H., Shinohara E.T., Cai Q., Chen H., Courtney R., Cao C., et al. Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer. Clin Oncol (R Coll Radiol) 18 4 (2006) 333-337
28. Jorgenson E., Deitcher S.R., Cicek M., Liu X., Plummer S., Casey G., et al. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history. Prostate 67 2 (2007) 172-177
29. Castello R., Espana F., Vazquez C., Fuster C., Almenar S.M., Aznar J., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 117 5 (2006) 487-492
30. Lei H, Hemminki K, Johansson R, Altieri A, Enquist K, Henriksson R, et al. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat 2007.
31. Sternlicht M.D., Dunning A.M., Moore D.H., Pharoah P.D., Ginzinger D.G., Chin K., et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomar Prev 15 11 (2006) 2107-2114
32. Vairaktaris E., Yapijakis C., Serefoglou Z., Vylliotis A., Ries J., Nkenke E., et al. Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42 9 (2006) 888-892
33. Smolarz B., Blasiak J., Kulig A., Romanowicz-Makowska H., Dziki A., Ulanska J., et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J Exp Clin Cancer Res 20 2 (2001) 247-252
34. Loktionov A., Watson M.A., Stebbings W.S., Speakman C.T., and Bingham S.A. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett 189 2 (2003) 189-196
35. Sciacca F.L., Ciusani E., Silvani A., Corsini E., Frigerio S., Pogliani S., et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 10 4 (2004) 1312-1317
36. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., and Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44 (1985) 139-266
37. American Cancer Society. Cancer facts and figures 2007. www.cancer.org.
38. Shiomi H., Eguchi Y., Tani T., Kodama M., and Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 156 2 (2000) 567-575
39. Ji F., Chen Y.L., Jin E.Y., Wang W.L., Yang Z.L., and Li Y.M. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 11 21 (2005) 3222-3226
40. Zhang L., Zhao Z.S., Ru G.Q., and Ma J. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 12 25 (2006) 3970-3976
41. Stephens R.W., Nielsen H.J., Christensen I.J., Thorlacius-Ussing O., Sorensen S., Dano K., et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91 10 (1999) 869-874
42. Riisbro R., Christensen I.J., Nielsen H.J., Brunner N., Nilbert M., and Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers 20 2 (2005) 93-102
43. Kim T.D., Song K.S., Li G., Choi H., Park H.D., Lim K., et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 6 (2006) 211
44. Bauer T.W., Liu W., Fan F., Camp E.R., Yang A., Somcio R.J., et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65 17 (2005) 7775-7781
45. Nielsen A., Scarlett C.J., Samra J.S., Gill A., Li Y., Allen B.J., et al. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol 20 2 (2005) 256-263
46. Harvey S.R., Hurd T.C., Markus G., Martinick M.I., Penetrante R.M., Tan D., et al. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 9 13 (2003) 4935-4943
47. Gutova M., Najbauer J., Gevorgyan A., Metz M.Z., Weng Y., Shih C.C., et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2 (2007) e243
48. Shetty S., Kumar A., Johnson A., Pueblitz S., and Idell S. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am J Physiol 268 6 Pt 1 (1995) L972-L982
49. Perkins R.C., Broaddus V.C., Shetty S., Hamilton S., and Idell S. Asbestos upregulates expression of the urokinase-type plasminogen activator receptor on mesothelial cells. Am J Respir Cell Mol Biol 21 5 (1999) 637-646
50. Hackel C., Czerniak B., Ayala A.G., Radig K., and Roessner A. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer 79 1 (1997) 53-58
51. Hackel C.G., Krueger S., Grote H.J., Oshiro Y., Hodges S., Johnston D.A., et al. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer 89 5 (2000) 995-1003
52. Romer J., Pyke C., Lund L.R., Ralfkiaer E., and Dano K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J Invest Dermatol 116 3 (2001) 353-358
53. Duffy M.J., Duggan C., Mulcahy H.E., McDermott E.W., and O'Higgins N.J. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 44 6 Pt 1 (1998) 1177-1183
54. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94 2 (2002) 116-128
55. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60 3 (2000) 636-643
56. Harbeck N., Kates R.E., Schmitt M., Gauger K., Kiechle M., Janicke F., et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5 5 (2004) 348-352
57. Janicke F., Prechtl A., Thomssen C., Harbeck N., Meisner C., Untch M., et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93 12 (2001) 913-920
58. Memarzadeh S., Kozak K.R., Chang L., Natarajan S., Shintaku P., Reddy S.T., et al. Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer. Proc Natl Acad Sci USA 99 16 (2002) 10647-10652
59. Chambers S.K., Gertz Jr. R.E., Ivins C.M., and Kacinski B.M. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75 7 (1995) 1627-1633
60. Li H., Ye X., Mahanivong C., Bian D., Chun J., and Huang S. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 280 11 (2005) 10564-10571
61. Pulukuri S.M., Gondi C.S., Lakka S.S., Jutla A., Estes N., Gujrati M., et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280 43 (2005) 36529-36540
62. Piironen T., Haese A., Huland H., Steuber T., Christensen I.J., Brunner N., et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 52 5 (2006) 838-844
63. Shariat S.F., Roehrborn C.G., McConnell J.D., Park S., Alam N., Wheeler T.M., et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25 4 (2007) 349-355
64. Ornstein D.L., and Zacharski L.R. Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. Nutr Cancer 58 1 (2007) 115-126
65. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metast Rev 20 3-4 (2001) 287-296
66. Los M., Zeamari S., Foekens J.A., Gebbink M.F., and Voest E.E. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res 59 17 (1999) 4440-4445
67. Hsu D.W., Efird J.T., and Hedley-Whyte E.T. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147 1 (1995) 114-123
68. Bu X., Khankaldyyan V., Gonzales-Gomez I., Groshen S., Ye W., Zhuo S., et al. Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab Invest 84 6 (2004) 667-678
69. Ragno P., Montuori N., Covelli B., Hoyer-Hansen G., and Rossi G. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells. Cancer Res 58 6 (1998) 1315-1319
70. Scherrer A., Wohlwend A., Kruithof E.K., Vassalli J.D., and Sappino A.P. Plasminogen activation in human acute leukaemias. Br J Haematol 105 4 (1999) 920-927
71. Aref S., El-Sherbiny M., Mabed M., Menessy A., and El-Refaei M. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion. Hematology 8 6 (2003) 385-391
72. Graf M., Reif S., Hecht K., Pelka-Fleischer R., Pfister K., and Schmetzer H. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis. Am J Hematol 79 1 (2005) 26-35
73. Pillay V., Dass C.R., and Choong P.F. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25 1 (2007) 33-39
74. Margheri F., D'Alessio S., Serrati S., Pucci M., Annunziato F., Cosmi L., et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther 12 8 (2005) 702-714
75. Wang Y., Liang X., Wu S., Murrell G.A., and Doe W.F. Inhibition of colon cancer metastasis by a 3′-end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer 92 2 (2001) 257-262
76. Gondi C.S., Lakka S.S., Dinh D.H., Olivero W.C., Gujrati M., and Rao J.S. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23 52 (2004) 8486-8496
77. Kong D., Li Y., Wang Z., Banerjee S., and Sarkar F.H. Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67 7 (2007) 3310-3319
78. Ustach C.V., and Kim H.R. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25 14 (2005) 6279-6288
79. Fredriksson L., Li H., Fieber C., Li X., and Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23 19 (2004) 3793-3802
80. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3 10 (2003) 768-780
81. Sarkar F.H., and Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66 7 (2006) 3347-3350
82. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65 15 (2005) 6934-6942
83. Banerjee S., Zhang Y., Ali S., Bhuiyan M., Wang Z., Chiao P.J., et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65 19 (2005) 9064-9072
84. Lev-Ari S., Strier L., Kazanov D., Madar-Shapiro L., Dvory-Sobol H., Pinchuk I., et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 11 18 (2005) 6738-6744
85. Jazirehi A.R., and Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 3 1 (2004) 71-84
86. Sarkar F.H., and Li Y. Indole-3-carbinol and prostate cancer. J Nutr 134 12 Suppl (2004) 3493S-3498S
87. Chisholm K., Bray B.J., and Rosengren R.J. Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs 15 9 (2004) 889-897
88. Li Y., and Sarkar F.H. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 186 2 (2002) 157-164